EPA-0626 – Long-term Safety of Methylphenidate Hydrochloride Modified Release (MPH-LA) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
EUROPEAN PSYCHIATRY(2014)
摘要
A previous 40-week, randomised, double-blind placebo-controlled core study [comprising of dose confirmation (9-week), real-life dose optimisation (5-week) and maintenance of effect phases (6-month)] reported the safety of MPH-LA in the treatment of adult ADHD. Here, we report the long-term safety from the extension phase (6-month) of this core study. During the extension phase, patients initiated treatment with MPH-LA 20 mg/day; up-titrated to an optimal dose of 40, 60 or 80 mg/day in increments of 20 mg/week. Safety was analysed from baseline of maintenance of effect phase (core study); and from baseline of extension phase to end of extension phase. Adverse events (AEs) and serious adverse events (SAEs) were reported. Incidence of AEs occurring anytime starting from baseline of the maintenance of effect phase (core study) until the end of extension phase was 80.5%. The incidence of AEs occurring in the extension phase period was 69.8% (Table). Incidence of serious AEs (SAEs) reported during both periods were similar (0.7%). Most common AEs were nasopharyngitis, headache, decreased appetite, dry mouth and nausea. No deaths were reported. No new or unexpected results were observed for laboratory findings, vital signs or ECGs. None of the patients had QT, QTcB or QTcF ≥500ms during the study. Long-term treatment with MPH-LA in adult ADHD patients was well-tolerated.Table: Number (%) of patients with most frequent AEs and SAEsAEs occuring anytime starting from the baseline of maintenance of effect phase (core study) to the end of extension phaseAEs occuring anytime in the extension phase(Preferred Term ≥5%)N=298 n (%)N=298 n (%)Total AEs240(80.5)208(69.8) Nasopharyngitis79(26.5)57(19.1) Headache62(20.8)42(14.1) Decreased appetite26(8.7)23 (7.7) Dry mouth24(8.1)20 (6.7) Nausea18(6.0)15 (5.0) Upper respiratory tract infection17(5.7)14(4.7) Diarrhoea15(5.0)6 (2.0)Total SAEs2(0.7)2(0.7) Pancreatitis1 (0.3)1 (0.3) Exostosis1 (0.3)1 (0.3) Non-Hodgkin's lyrnphorna1 (0.3)1 (0.3) Table: Number (%) of patients with most frequent AEs and SAEs
更多查看译文
关键词
ADHD,Attention-Deficit/Hyperactivity Disorder,Treatment,Medication Adherence
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要